VytronUS

Headquartered in California's Silicon Valley, Vytronus, Inc. was formed in 2006 to harness the imaging and therapeutic capabilities of ultrasound energy to treat cardiac arrhythmias, starting with atrial fibrillation. The company believes that a new energy source, such as collimated ultrasound, is amenable to automation and capable of both imaging... and ablating, thus shifting the treatment paradigm to more predictable outcomes. The company strives to make a complicated procedure simple. Ease of use guides every aspect of the company's design philosophy. At Vytronus, patient safety is always the company's first priority and improved efficacy is the company's mission. The company look forward to obtaining regulatory approvals and making the company's products available to doctors and their patients in the near future.Read More